Short Interest in Aptevo Therapeutics Inc. (NASDAQ:APVO) Drops By 92.1%

Aptevo Therapeutics Inc. (NASDAQ:APVO) was the recipient of a large decline in short interest in January. As of January 15th, there was short interest totalling 19,000 shares, a decline of 92.1% from the December 31st total of 241,700 shares. Based on an average daily volume of 325,400 shares, the short-interest ratio is presently 0.1 days. Approximately 1.3% of the company’s shares are sold short.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on Aptevo Therapeutics in a research note on Monday, December 9th. They set a “sell” rating on the stock.

Aptevo Therapeutics Stock Up 3.3 %

Shares of Aptevo Therapeutics stock traded up $0.15 during trading on Tuesday, hitting $4.64. 35,964 shares of the stock traded hands, compared to its average volume of 67,267. Aptevo Therapeutics has a twelve month low of $3.65 and a twelve month high of $399.60. The company has a fifty day moving average price of $97.86 and a two-hundred day moving average price of $303.60.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.